Valeant launches hostile $53B bid for Allergan

Valeant Pharmaceuticals said Wednesday it has launched a tender offer for Allergan, the maker of Botox, taking its hostile bid directly to shareholders.

The cash and stock offer values Allergan Inc. at around $53 billion, and it expires Aug. 15.

Allergan said it will review the offer and said shareholders shouldn't take action on the right now.

Valeant, which is based in Canada, has teamed up with Bill Ackman's Pershing Square Capital Management to try to purchase Allergan. The two companies went public with their takeover attempt in April and have increased their original bid of about $45.6 billion several times.

Allergan, of Irvine, California, has said the latest offer is still too low.

Ackman—whose Pershing Square is Allergan's biggest —is also moving to replace most of Allergan's board.

On Tuesday Valeant Pharmaceuticals International Inc. said it planned to take a buyout offer directly to Allergan shareholders this week.

Allergan shares rose $1.74 to $162.27 in morning trading. Valeant stock added 13 cents to $119.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Valeant planning hostile bid for Allergan

Jun 17, 2014

Valeant plans to take a buyout offer for Allergan directly to its shareholders this week, as the Botox maker continues to rebuff its proposals that have risen as high as $53 billion.

Recommended for you

Were clinical trial practices in East Germany questionable?

10 hours ago

Clinical trials carried out in the former East Germany in the second half of the 20th century were not always with the full knowledge or understanding of participants with some questionable practices taking place, according ...

Schumacher's doctor sees progress after injury

Oct 23, 2014

A French physician who treated Michael Schumacher for nearly six months after the Formula One champion struck his head in a ski accident says he is no longer in a coma and predicted a possible recovery within three years.

User comments